home / stock / gtbp / gtbp news

GTBP News and Press, GT Biopharma Inc. From 10/03/19

Stock Information
Company Name: GT Biopharma Inc.
Stock Symbol: GTBP
Market: OTC
Website: gtbiopharma.com
Menu
GTBP GTBP Quote GTBP Short GTBP News GTBP Articles GTBP Message Board
Get GTBP Alerts

News, Short Squeeze, Breakout and More Instantly...
GTBP - GT Biopharma Announces HIV TriKE(TM) Data Demonstrating NK Cell Killing of Patient HIV Infected Cells

TAMPA, Florida , Oct. 3, 2019 /PRNewswire/ -- GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA), an immuno-oncology company focused on innovative treatments based on the Company's patent pending TriKE™ technology, announced today that Tim Schacker , M.D., Jeffrey S. Miller , M.D., and t...
GTBP - GT Biopharma Announces HIV Trike(TM) Data to be Published

LOS ANGELES , Sept. 26, 2019 /PRNewswire/ -- GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA) an immuno-oncology company focused on innovative treatments based on the Company's proprietary NK cell engager (TriKE™) platform, announced today that Dr. Jeffrey Miller and colleagues from th...

GTBP - GT Bio sells GTB-004 rights to DAS Therapeutics

GT Biopharma ( OTCQB:GTBP ) has sold the rights to GTB-004 for the treatment of myasthenia gravis to DAS Therapeutics. More news on: GT Biopharma, Inc., Healthcare stocks news, Read more ...

GTBP - GT Biopharma Announces the Sale of Its Fixed Dose Combination Tablet (GTB-004) for Myasthenia Gravis (Chronic Autoimmune Disease) to DAS Therapeutics

GT Biopharma Announces the Sale of Its Fixed Dose Combination Tablet (GTB-004) for Myasthenia Gravis (Chronic Autoimmune Disease) to DAS Therapeutics Canada NewsWire TAMPA, Florida, Sept. 24, 2019 TAMPA, Florida , Sept. 24, 2019 /CNW/ -- GT Biopharma, Inc. (OTCQB: GTBP) (...
GTBP - GT Bio to commence patient enrollment in human GTB-3550 Trike mid-stage trial

GT Biopharma ( OTCQB:GTBP ) has notified FDA that it was commencing enrollment in its first-in-human GTB-3550 Phase I/II clinical trial. More news on: GT Biopharma, Inc., Healthcare stocks news, Read more ...

GTBP - GT Biopharma Announces FDA Notification of Commencement of Enrollment in Human GTB-3550 Trike(TM) Phase i/ii Clinical Trial

TAMPA, Florida , Sept. 12, 2019 /PRNewswire/ -- GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA) an immuno-oncology company focused on innovative treatments based on the Company's proprietary NK cell engager (TriKE™) platform and Multi-Target Directed Bispecific Drug Conjugate platform, ...

GTBP - GT Biopharma Hires Chief Medical Officer Jeffery Miller, M.D.

TAMPA, FL / ACCESSWIRE / August 20, 2019 / GT Biopharma, Inc. (OTCQB:GTBP) (GTBP.PA) an immuno-oncology company focused on innovative treatments based on the Company's proprietary NK cell engager (TriKE™) platform and Multi-Target Directed Bispecific Drug Conjugate platform, anno...
GTBP - GT Biopharma GTB-1550

Multi-Targeted Bispecific Drug Conjugate Strategically positioned in new class of ADC Drugs TAMPA, Florida , June 13, 2019 /PRNewswire/ -- GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA) an immuno-oncology company developing GTB-1550, a novel multi-target bispecific drug conjugate ther...

GTBP - 4 Biotech Stocks to Watch After Latest Merger and Acquisition Activity

CORAL GABLES, FL / ACCESSWIRE / June 11, 2019 / This month the American Society of Clinical Oncology held its annual meeting in Chicago, which brought about more attention to the healthcare sector and biotechstocks . The recent deal between Merck and Tilos Therapeutics has sparked increased...

GTBP - GT Biopharma Company Update

TAMPA, Florida , June 10, 2019 /PRNewswire/ -- GT Biopharma, Inc. (OTCQB: GTBP) (OTCQB: GTBP.PA) an immuno-oncology company focused on innovative treatments based on the Company's proprietary NK cell engager (TriKE) platform and Multi-Target Directed Bispecific Drug Conjugate (MTBDC) plat...
Previous 10 Next 10